Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 in San Francisco. Krish S. Krishnan, chairman and CEO, is scheduled to present at 10:30 am ET / 7:30 am PT and will host investor meetings throughout the day. A webcast of the presentation will be available beginning at 10:30 am ET / 7:30 am PT on January 12, 2026 and will be posted in the Investors section of the company website.
Details
News Market Reaction – KRYS
On Jan 5, the day this news came out, KRYS closed 0.89% below the previous close.
Data tracked by StockTitan Argus for the Jan 5 session.
Key Figures
- Conference edition
- 44th
- 44th Annual J.P. Morgan Healthcare Conference
- Conference date
- January 12, 2026
- Scheduled presentation date in San Francisco
- Presentation time ET
- 10:30 am ET
- J.P. Morgan Healthcare Conference slot
- Presentation time PT
- 7:30 am PT
- Local time for conference presentation
Historical Context
-
Announcement of Evercore healthcare conference appearance and webcast details.
-
Reported strong Q3 2025 revenue, margins, cash and global VYJUVEK rollout.
-
Scheduled Q3 2025 results call and provided webcast and replay information.
-
FDA platform technology designation for HSV-1 vector used in KB801.
-
FDA approval of updated VYJUVEK label expanding eligibility and at-home use.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a presentation at 10:30 am ET / 7:30 am PT and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 10:30 am ET / 7:30 am PT on Monday, January 12, 2026 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.